Randomized Phase 2 Trial Evaluating the Addition of the IGF-lR Monoclonal Antibody Ganitumab (AMG479, NSC#750008, IND#120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Submitted by centretek on Sat, 10/15/2022 - 10:29
Source URL
https://www.inova.org/clinical-trials/randomized-phase-2-trial-evaluating-addition-igf-lr-monoclonal-antibody-ganitumab
Description
General Information Age Group Status Active Protocol Number AEWS1221 Offered At Inova Children's Hospital 3300 Gallows Road Falls Church, VA 22042 Contact Information Contact Name Keary Jane't Contact Phone 703-776-3456 Contact Email Send Email
Clinical Trials Category
Cancer
Clinical Trials Sub categories
Ewing Sarcoma
Crawled Content Type
Clinical Trials
Featured Content
Off
Summary
Randomized Phase 2 Trial Evaluating the Addition of the IGF-lR Monoclonal Antibody Ganitumab (AMG479, NSC#750008, IND#120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Hide in search
Off
is_synonym
Off
Also a children's page
Off